Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (23722)	5/21/2007 6:50:37 PM
From: CrazyPete	Respond to of 52153

What you're saying is true (that statistical significance is a poor measure of practical importance), however, an odds ratio is a measure of effect size hence it is closer to being a measure of importance. I would not poo-poo an odds ratio of 1.64 for death due to MI. Especially since one might hope that a diabetes drug would reduce incidence of cardiovascular events. That said, I'd rather see the long-term data that showed no evidence for increased risk, according to GSK. One wonders about the wording of their statement, since it would be consistent with their studies being under-powered. A stronger statement that they could have made, but didn't, would be that their long-term data was inconsistent with the reported increase in risk. But who knows if that was intentional.